|Sunesis Pharmaceuticals, Inc.|
395 Oyster Point Boulevard
South San Francisco,
United States - Map
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.
|Sunesis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Daniel N. Swisher Jr.,
Chief Exec. Officer, Pres and Director
|Mr. Eric H. Bjerkholt ,
Chief Financial Officer, Exec. VP of Corp. Devel. & Fin. and Corp. Sec.
|Dr. Adam R. Craig M.D., Ph.D., M.B.A.,
Chief Medical Officer and Exec. VP of Devel.
|Mr. Gene C. Jamieson ,
VP of Technical Operations
|Dr. Mary G. Bolton M.D., Ph.D.,
VP of Clinical Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|